tetano
Editor, Senior Moderator
Medicine (Baltimore)
. 2022 Jun 24;101(25):e29364.
doi: 10.1097/MD.0000000000029364.
Case fatality rate of the adult in-patients with COVID-19 and digestive system tumors: A systematic review and meta-analysis
Guoqun Wang[SUP] 1 [/SUP], Lanlan Pan[SUP] 2 [/SUP], Jianyi Zhao[SUP] 3 [/SUP], Jie Tang[SUP] 4 [/SUP], Yueyu Fang[SUP] 1 [/SUP], Hui Sun[SUP] 1 [/SUP], Poshita Kumari Seesaha[SUP] 3 [/SUP], Wensen Chen[SUP] 5 6 [/SUP], Xiaofeng Chen[SUP] 1 2 [/SUP]
Affiliations
Abstract
Background: During the coronavirus disease 2019 (COVID-19) pandemic, endoscopic screening for gastrointestinal tumors was suspended or delayed in most countries. Thus, our study aimed to quantify the impact of COVID-19 on the clinical outcomes of patients with digestive system tumors through a systematic review and meta-analysis.
Methods: We systematically searched the PubMed, Web of Science, Cochrane Library, and Embase databases as of March 7, 2021 to identify the case fatality rate (CFR) of COVID-19 patients diagnosed with digestive system tumors. A random-effects model was used for meta-analysis, I2 was used to assess heterogeneity, and funnel plot was used to assess publication bias.
Results: A total of 13 studies were included, involving 2943 tumor patients with COVID-19, of which 871 were digestive system tumors, and the CFR was 24% (95% CI, 18%-30%; I2 = 55.7%). The mortality rate of colorectal cancer was 21% (95% CI, 14%-27%; I2 = 0.0%), gastric cancer was 25% (95% CI, 6%-45%; I2 = 0.0%), and hepatobiliary cancer was 29%. In general, there was no significant difference in the CFR of digestive system tumors.
Conclusion: The combined CFR of digestive system tumors and COVID-19 patients was 24%, which is much higher than that of the general population. Under the premise of fully complying with the international guidelines to limit the spread of COVID-19, we call for the resumption of endoscopic screening programs and selective surgery as soon as possible.
Registration information: PROSPERO registration no. CRD42021248194.
. 2022 Jun 24;101(25):e29364.
doi: 10.1097/MD.0000000000029364.
Case fatality rate of the adult in-patients with COVID-19 and digestive system tumors: A systematic review and meta-analysis
Guoqun Wang[SUP] 1 [/SUP], Lanlan Pan[SUP] 2 [/SUP], Jianyi Zhao[SUP] 3 [/SUP], Jie Tang[SUP] 4 [/SUP], Yueyu Fang[SUP] 1 [/SUP], Hui Sun[SUP] 1 [/SUP], Poshita Kumari Seesaha[SUP] 3 [/SUP], Wensen Chen[SUP] 5 6 [/SUP], Xiaofeng Chen[SUP] 1 2 [/SUP]
Affiliations
- PMID: 35758367
- DOI: 10.1097/MD.0000000000029364
Abstract
Background: During the coronavirus disease 2019 (COVID-19) pandemic, endoscopic screening for gastrointestinal tumors was suspended or delayed in most countries. Thus, our study aimed to quantify the impact of COVID-19 on the clinical outcomes of patients with digestive system tumors through a systematic review and meta-analysis.
Methods: We systematically searched the PubMed, Web of Science, Cochrane Library, and Embase databases as of March 7, 2021 to identify the case fatality rate (CFR) of COVID-19 patients diagnosed with digestive system tumors. A random-effects model was used for meta-analysis, I2 was used to assess heterogeneity, and funnel plot was used to assess publication bias.
Results: A total of 13 studies were included, involving 2943 tumor patients with COVID-19, of which 871 were digestive system tumors, and the CFR was 24% (95% CI, 18%-30%; I2 = 55.7%). The mortality rate of colorectal cancer was 21% (95% CI, 14%-27%; I2 = 0.0%), gastric cancer was 25% (95% CI, 6%-45%; I2 = 0.0%), and hepatobiliary cancer was 29%. In general, there was no significant difference in the CFR of digestive system tumors.
Conclusion: The combined CFR of digestive system tumors and COVID-19 patients was 24%, which is much higher than that of the general population. Under the premise of fully complying with the international guidelines to limit the spread of COVID-19, we call for the resumption of endoscopic screening programs and selective surgery as soon as possible.
Registration information: PROSPERO registration no. CRD42021248194.